TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12969696

Group type: EXPERIMENTAL
Intervention: Transdermal E(2) (50 microg)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Oral E(2) (1 mg)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Oral E(2) (1 mg) combined with gestodene (25 microg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 10231049

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 8917263

Group type: EXPERIMENTAL
Intervention: Vein grafts
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ungrafted coronary arteries
Number of subjects: 95
Study: 1986889

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 33

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 33
Study: 6366138

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate dosage regimen derived from CNS volume considerations (CCG-160 series)
Number of subjects: 3241

Group type: COMPARATOR
Intervention: Standard therapy with cranial irradiation (2400 rads) and intrathecal methotrexate (12 mg/m2 six times during consolidation) (CCG-141)
Number of subjects: 3241

Group type: COMPARATOR
Intervention: Modification of CCG-141 with intrathecal methotrexate initiated during induction (CCG-141A)
Number of subjects: 3241

Group type: COMPARATOR
Intervention: Maintenance intrathecal chemotherapy
Number of subjects: 3241

Group type: EXPERIMENTAL
Intervention: Overall treatment strategy
Number of subjects: 3241
Study: 3512188

Group type: EXPERIMENTAL
Intervention: 200 micrograms of fenoterol by metered-dose inhaler
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 micrograms of fenoterol by metered-dose inhaler
Number of subjects: 20

Group type: COMPARATOR
Intervention: isoproterenol
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 29212358

Group type: COMPARATOR
Intervention: Family-based intervention delivered by community health workers over 11 sessions for 4 months.
Number of subjects: 361
Study: 29127418

Group type: EXPERIMENTAL
Intervention: Pattern search
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Exploration
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Recency
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall pattern search belief
Number of subjects: 84
Study: 26545996

Group type: EXPERIMENTAL
Intervention: Foot reflexology applied for 40 min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 24294687

Group type: EXPERIMENTAL
Intervention: Debridement (at postoperative weeks 2 and 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No debridement
Number of subjects: 0
Study: 21208574

Group type: EXPERIMENTAL
Intervention: eszopiclone cotherapy with SSRI (3 mg/d)
Number of subjects: 347

Group type: COMPARATOR
Intervention: placebo cotherapy
Number of subjects: 347
Study: 18376044

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 16491339

Group type: EXPERIMENTAL
Intervention: Articaine 4% with epinephrine 1:200,000
Number of subjects: 155

Group type: COMPARATOR
Intervention: Articaine 2% with epinephrine 1:200,000
Number of subjects: 155
Study: 12734787

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg, TID, over 90 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10952250

Group type: COMPARATOR
Intervention: 6 million units of IFN once a day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 3 million units of IFN twice a day
Number of subjects: 22
Study: 9291768

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 8337057

Group type: EXPERIMENTAL
Intervention: Resistive training program using the Body Bar
Number of subjects: 30

Group type: COMPARATOR
Intervention: Walking program (control)
Number of subjects: 30
Study: 2952685

Group type: EXPERIMENTAL
Intervention: Erythromycin 2% gel
Number of subjects: 102

Group type: COMPARATOR
Intervention: Clindamycin phosphate 1% solution
Number of subjects: 102
Study: 28872368

Group type: EXPERIMENTAL
Intervention: PCMcold (cooled to 15°C)
Number of subjects: 11
Study: 27062040

Group type: EXPERIMENTAL
Intervention: Hereditary group H++ (both parents myopic)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hereditary group H+– (one myopic parent)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Hereditary group H– (no myopic parents)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Myopic progression among females with myopic parents
Number of subjects: 240

Group type: COMPARATOR
Intervention: Myopic progression among females with non-myopic parents
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Follow-up end among males
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Follow-up end among females
Number of subjects: 240
Study: 24612414

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1mg/kg loading dose prior to incision, continuous dose of 1mg/kg/h for 24h)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (5mL saline loading dose, continuous dose of 90mg ketorolac in 240mL saline)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 77
Study: 23614819

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine injection
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal saline injection (placebo)
Number of subjects: 34
Study: 20958890

Group type: EXPERIMENTAL
Intervention: Zinc (90 mg)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Zinc plus retinol (5000 IU)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Zinc plus retinol
Number of subjects: 350
Study: 18191012

Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer (GI/GV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer (GII/GVI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Composite resin (GIII/GVII)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amalgam (GIV/GVIII)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saliva (control group)
Number of subjects: 10
Study: 16892428

Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GP IIb/IIIa blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin with GP IIb/IIIa inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 12562653

Group type: EXPERIMENTAL
Intervention: Modified CHOP (cyclophosphamide 600 mg/m² i.v., doxorubicin 30 mg/m² i.v., vincristine 1 mg i.v. on day 1 with prednisolone 20 mg bd for days 1-5) every 21 days
Number of subjects: 155

Group type: COMPARATOR
Intervention: MCOP (mitozantrone 10 mg/m² i.v. substituted for doxorubicin)
Number of subjects: 155
Study: 10868022

Group type: EXPERIMENTAL
Intervention: Day-patient treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0
Study: 9339937

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) devices applied for 120 minutes
Number of subjects: 12
Study: 8219141

Group type: EXPERIMENTAL
Intervention: Midazolam/Tramadol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo/Tramadol
Number of subjects: 40
Study: 3895937

Group type: EXPERIMENTAL
Intervention: Penicillin/Ampicillin
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 825
Study: 31833413

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography with FFRCT
Number of subjects: 223

Group type: COMPARATOR
Intervention: FFRCT assessment
Number of subjects: 223
Study: 27666149

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide-oxygen mixture (50% N2 O-O2)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Medical air (22% O2 - 78% N2)
Number of subjects: 66
Study: 26001996

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% plain
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of lidocaine 1% plain and bupivacaine 0.25%
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sequential injections of lidocaine 1% plain followed by bupivacaine 0.25% 1h later
Number of subjects: 3
Study: 23349357

Group type: EXPERIMENTAL
Intervention: Lightning days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-lightning days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Average current of lightning strikes
Number of subjects: 90
Study: 21573144

Group type: EXPERIMENTAL
Intervention: Cryptococcus neoformans variety grubii isolates from Thailand
Number of subjects: 183

Group type: COMPARATOR
Intervention: Comparison with global MLST database of 77 Cng isolates
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Genetic diversity analysis
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Divergence time testing
Number of subjects: 183
Study: 19620518

Group type: EXPERIMENTAL
Intervention: Fine particles (150 microg/m(3)) plus ozone (120 parts per billion) for 2 hours with Bosentan (250 mg) pretreatment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fine particles (150 microg/m(3)) plus ozone (120 parts per billion) for 2 hours with Vitamin C (2 g) pretreatment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fine particles (150 microg/m(3)) plus ozone (120 parts per billion) for 2 hours with placebo pretreatment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Particles plus ozone, particles, ozone, and filtered air in Toronto
Number of subjects: 81

Group type: COMPARATOR
Intervention: Filtered air in Toronto
Number of subjects: 81
Study: 16842608

Group type: EXPERIMENTAL
Intervention: Perfume exposure
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 42
Study: 14556866

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 5035

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 5035
Study: 10856394

Group type: EXPERIMENTAL
Intervention: Celiprolol (100 mg)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 9200388

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of nicorandil (2 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coronary revascularization only (Control)
Number of subjects: 20
Study: 8268898

Group type: EXPERIMENTAL
Intervention: Low dose diuretic therapy
Number of subjects: 0
Study: 2871219

Group type: EXPERIMENTAL
Intervention: 5 mg ketobemidon
Number of subjects: 67

Group type: COMPARATOR
Intervention: 50 mg indomethacin
Number of subjects: 67
Study: 29101645

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 593

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 593
Study: 27756477

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 3158

Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 3158
Study: 25239412

Group type: EXPERIMENTAL
Intervention: Histologic patterns in patients with isolated lymphadenopathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High numbers of IgG4-positive plasma cells
Number of subjects: 0
Study: 21782923

Group type: EXPERIMENTAL
Intervention: WM therapy
Number of subjects: 505

Group type: COMPARATOR
Intervention: CM therapy
Number of subjects: 505
Study: 20145433

Group type: EXPERIMENTAL
Intervention: 8 mg benidipine once daily (n = 20, group A)
Number of subjects: 40
Study: 17512157

Group type: EXPERIMENTAL
Intervention: Sweat patch testing
Number of subjects: 63
Study: 15823831

Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: estradiol 2 mg/norethisterone acetate 1 mg (E2/NETA)
Number of subjects: 166

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 166
Study: 11916779

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) 1.5 mg/kg before graft reperfusion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 36
Study: 9861558

Group type: EXPERIMENTAL
Intervention: Standardized diagnostic interventions
Number of subjects: 968
Study: 9893773

Group type: EXPERIMENTAL
Intervention: Low-dose formoterol Turbuhaler 6 micrograms b.i.d.
Number of subjects: 397

Group type: COMPARATOR
Intervention: Terbutaline 0.5 mg q.i.d.
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo from Turbuhaler
Number of subjects: 397
Study: 1679391

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA, 450 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 7060823

Group type: EXPERIMENTAL
Intervention: Sodium meclofenamate (300 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ibuprofen (900 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Spine movement)
Number of subjects: 30
Study: 30515705

Group type: EXPERIMENTAL
Intervention: Consumption of adequately iodized salt
Number of subjects: 1263

Group type: COMPARATOR
Intervention: Consumption of inadequately iodized salt
Number of subjects: 1263

Group type: COMPARATOR
Intervention: Presence of goitre
Number of subjects: 1263
Study: 26925992

Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage (SSBM) 3 times a week for 10 minutes over 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 22572632

Group type: EXPERIMENTAL
Intervention: 12-week exercise training (n=27)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Stretching control treatment (n=16)
Number of subjects: 43
Study: 21441781

Group type: EXPERIMENTAL
Intervention: REVAXIS
Number of subjects: 760

Group type: COMPARATOR
Intervention: DT Polio
Number of subjects: 760
Study: 19619443

Group type: EXPERIMENTAL
Intervention: TP regimen (docetaxel 70 mg/m² on Day 1 and DDP 80 mg/m² on Day 2 for induction; docetaxel 60 mg/m² on Day 1 and DDP 80 mg/m² on Day 2 for concurrent chemotherapy)
Number of subjects: 57

Group type: COMPARATOR
Intervention: DDP regimen (DDP 80 mg/m² on Day 1 for concurrent chemotherapy)
Number of subjects: 57
Study: 17764783

Group type: EXPERIMENTAL
Intervention: Pressure bag at 300 mm Hg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual push‐pull system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gravity
Number of subjects: 60
Study: 14980192

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 63

Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 63
Study: 11495215

Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (nonsmokers)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nicotine gum administration
Number of subjects: 60

Group type: COMPARATOR
Intervention: OC nonusers
Number of subjects: 60
Study: 9306352

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane (PAN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polysulphone (PS) membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acrylonitrile copolymer (AN 69) membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cuprophan (CUP) membrane
Number of subjects: 0
Study: 8216039

Group type: EXPERIMENTAL
Intervention: Scotchbond 2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Scotchbond 2 with dentine roughening
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tripton
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prisma Universal Bond 2
Number of subjects: 20
Study: 2893410

Group type: EXPERIMENTAL
Intervention: Suriclone (2 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Diazepam (25 mg/day)
Number of subjects: 33
Study: 29310679

Group type: EXPERIMENTAL
Intervention: Structured teleconference re‐visit with study personnel and commitment contract
Number of subjects: 810

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily
Number of subjects: 810
Study: 27723637

Group type: EXPERIMENTAL
Intervention: 0.2% hyaluronan gel adjunctive to scaling and root planing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing alone (Control)
Number of subjects: 20
Study: 24794469

Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring
Number of subjects: 40
Study: 22605573

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA)
Number of subjects: 6183

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 6183

Group type: COMPARATOR
Intervention: Total fat, polyunsaturated fatty acids (PUFA), and trans-fat
Number of subjects: 6183
Study: 20972340

Group type: EXPERIMENTAL
Intervention: Graded exercise
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Graded exposure
Number of subjects: 33

Group type: COMPARATOR
Intervention: Graded exercise and graded exposure (combined)
Number of subjects: 33
Study: 18689509

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (daughter strain)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactobacillus reuteri ATCC 55730 (parent strain)
Number of subjects: 0
Study: 15928070

Group type: EXPERIMENTAL
Intervention: High-dose carboplatin, etoposide and cyclophosphamide (CarboPEC) with haematopoietic stem cell support (arm B)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Conventional salvage chemotherapy (four cycles of cisplatin, ifosfamide and etoposide or vinblastine) (arm A)
Number of subjects: 280
Study: 12802484

Group type: EXPERIMENTAL
Intervention: Cefazolin (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (20 ml)
Number of subjects: 12
Study: 10595478

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sincalide
Number of subjects: 5

Group type: COMPARATOR
Intervention: Baseline (no medication)
Number of subjects: 5
Study: 8712441

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron (0.1 mg/kg for children ≤ 40 kg; 4 mg for children > 40 kg)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 1905476

Group type: EXPERIMENTAL
Intervention: Whole milk (50 g lactose/L)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acidified milk (24 g lactose/L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Commercial lactose-free diet (LFD)
Number of subjects: 50
Study: 6650578

Group type: EXPERIMENTAL
Intervention: Skills-training group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Coaching group
Number of subjects: 35

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 35
Study: 31782930

Group type: EXPERIMENTAL
Intervention: Vigorous-Intensity Continuous Training (VICT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Whole-body Tabata
Number of subjects: 68

Group type: COMPARATOR
Intervention: No-exercise control (CTL)
Number of subjects: 68
Study: 29856692

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) 1,000 mg on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles for six to eight cycles
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Rituximab (R) 375 mg/m2 on day 1 of each cycle for six to eight cycles
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) plus chemotherapy (bendamustine)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) plus chemotherapy (CHOP)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) plus chemotherapy (CVP)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Chemotherapy (CHOP)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Chemotherapy (bendamustine)
Number of subjects: 1202
Study: 26563148

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (5.5-month diet-exercise program with mindfulness training)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Active control group (5.5-month diet-exercise program without mindfulness training)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 194

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 194
Study: 25385735

Group type: EXPERIMENTAL
Intervention: PCA3 urinary assay
Number of subjects: 859
Study: 22017969

Group type: EXPERIMENTAL
Intervention: OROS-MPH
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 142
Study: 19560995

Group type: EXPERIMENTAL
Intervention: Isokinetic muscular strengthening exercises
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Bilateral knee static stretching and isokinetic exercises
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) stretching and isokinetic exercises
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (Group IV)
Number of subjects: 132
Study: 17620907

Group type: EXPERIMENTAL
Intervention: Emergency Severity Index
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Canadian Triage and Acuity Scale
Number of subjects: 486

Group type: COMPARATOR
Intervention: Emergency Severity Index vs. Canadian Triage and Acuity Scale
Number of subjects: 486
Study: 16386090

Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unfixed combination therapy of 0.5% timolol maleate and 1% dorzolamide hydrochloride
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 11786452

Group type: EXPERIMENTAL
Intervention: Intervention group (brief verbal advice and standard booklet)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Intervention group (declaration of commitment component)
Number of subjects: 540
Study: 9523808

Group type: EXPERIMENTAL
Intervention: 30 microg intrathecal clonidine with 2.5 microg intrathecal sufentanil
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 30 microg intrathecal clonidine with 5 microg intrathecal sufentanil
Number of subjects: 98

Group type: COMPARATOR
Intervention: 5 microg intrathecal sufentanil alone
Number of subjects: 98
Study: 7662176

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 0
Study: 2547470

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril and Ramipril
Number of subjects: 20
Study: 821986

Group type: EXPERIMENTAL
Intervention: 4% cromolyn sodium
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31577797

Group type: EXPERIMENTAL
Intervention: Group antenatal care (G-ANC)
Number of subjects: 1844